A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the effectiveness and safety of CNTO 1275 in patients with Multiple Sclerosis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centocor, Inc.
• Collaborator: Centocor BV
• Treatments: Ustekinumab

Criteria

Inclusion Criteria:

• Have a definite diagnosis of Relapsing remitting Multiple Sclerosis

• Have a history of at least 1 of the following:a. A minimum of 2 relapses of MS within the previous 2 years but not within the 1-month period prior to screening. b. A relapse of MS within the previous 6 months but not within the 1-monthperiod prior to screening

Exclusion Criteria:

• Have a CNS disease (eg, CNS lymphoma, systemic lupus erythematous)

• Have significant bulbar involvement of MS or other neurologic deficits

• Have a decubitus ulcer

• Have received immunomodulatory therapies within 3 months of screening